1-11 of 11
Frank Campana
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, Kerry J. Savage, Tim Illidge, Swaminathan P Iyer, Ranjana Advani, Andrei R Shustov, Nancy L. Bartlett, Barbara Pro, Eric D Jacobsen, Raphael Koch, Domingo Domenech Eva, Michelle A. Fanale, Keenan Fenton, Frank Campana, Cassie Dong, Lorenz Truemper
Journal: Blood
Blood (2021) 138 (Supplement 1): 135.
https://doi.org/10.1182/blood-2021-145124
Published: 2021
Journal Articles

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Fredrik H. Schjesvold, MD PhD, Paul G. Richardson, MD, Michel Attal, MD PhD, Thierry Facon, MD, Adrián Alegre, MD, Andrew Spencer, DM, Artur Jurczyszyn, MD, Kazutaka Sunami, MD PhD, Laurent Frenzel, MD PhD, Chang-Ki Min, MD PhD, Solenn Le-Guennec, Frank Campana, MD, Helgi van de Velde, MD PhD, Samira Bensfia, MD, Sara Bringhen
Journal: Blood
Blood (2019) 134 (Supplement_1): 1893.
https://doi.org/10.1182/blood-2019-128010
Published: 2019
Journal Articles

Exposure-Response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma

Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel-Dedieu, Bernard Sebastien, Hoai-Thu Thai, Raouf El-Cheikh, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Li Liu, Frank Campana, MD, Helgi van de Velde, MD PhD, Christine Veyrat-Follet, Dorothee Semiond, PhD PharmD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1897.
https://doi.org/10.1182/blood-2019-128875
Published: 2019
Journal Articles

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

Paul G. Richardson, MD, Joseph Mikhael, MD FRCPC, MD, Thierry Facon, MD, William I. Bensinger, Sandrine Macé, Marielle Chiron, Helgi van de Velde, MD PhD, Frank Campana, MD, Li Liu, Michel Attal, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3179.
https://doi.org/10.1182/blood-2019-128071
Published: 2019
Journal Articles

Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Cyrille Hulin, MD, Paul G. Richardson, MD, Michel Attal, MD PhD, Hugh J. Goodman, FRACP, Vadim A Doronin, MD, Ivan Spicka, MD PhD Prof, Solenn Le-Guennec, Frank Campana, MD, Helgi van de Velde, MD PhD, Meral Beksac, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3185.
https://doi.org/10.1182/blood-2019-129840
Published: 2019
Journal Articles

Evaluating Isatuximab Interference with Monoclonal Protein Detection By Immuno-Capture and Liquid Chromatography Coupled to High Resolution Mass Spectrometry in the Pivotal Phase 3 Multiple Myeloma Trial, Icaria-MM

Greg Finn, PhD, Sandrine Macé, Frank Campana, MD, Solenn Le-Guennec, Stephané Muccio, Alexandra Tavernier, Marie-Claude Rouchon, Alain Roccon, Shujia Dai, Valérie Boutet, Dominique Mouret, Béatrice Pradeilles, Sébastien Hugla, Graziella Engelvin, Deborah DiNoto, Helgi van de Velde, MD PhD, Olivier Fedeli
Journal: Blood
Blood (2019) 134 (Supplement_1): 3143.
https://doi.org/10.1182/blood-2019-129963
Published: 2019
Journal Articles

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Clinical Trials & Observations
Joseph Mikhael, Paul Richardson, Saad Z. Usmani, Noopur Raje, William Bensinger, Chatchada Karanes, Frank Campana, Dheepak Kanagavel, Franck Dubin, Qianying Liu, Dorothée Semiond, Kenneth Anderson
Journal: Blood
Blood (2019) 134 (2): 123–133.
https://doi.org/10.1182/blood-2019-02-895193
Published: 2019
Journal Articles

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Clinical Trials & Observations
Thomas Martin, Rachid Baz, Don M. Benson, Nikoletta Lendvai, Jeffrey Wolf, Pamela Munster, Alexander M. Lesokhin, Claudine Wack, Eric Charpentier, Frank Campana, Ravi Vij
Journal: Blood
Blood (2017) 129 (25): 3294–3303.
https://doi.org/10.1182/blood-2016-09-740787
Published: 2017
Journal Articles

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Thomas G. Martin, III, MD, Gabriel N Mannis, Ajai Chari, MD, Pamela Munster, MD, Frank Campana, MD, Ai-Min Hui, MD PhD, Jeffrey L. Wolf, MD
Journal: Blood
Blood (2016) 128 (22): 2111.
https://doi.org/10.1182/blood.V128.22.2111.2111
Published: 2016
Journal Articles

Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Paul G. Richardson, MD, Joseph Mikhael, MD, Saad Z Usmani, MD FACP, Noopur Raje, MD, William Bensinger, MD, Frank Campana, MD, Lei Gao, Franck Dubin, Claudine Wack, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2016) 128 (22): 2123.
https://doi.org/10.1182/blood.V128.22.2123.2123
Published: 2016
Journal Articles

A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Thomas G. Martin, MD, Rachid Baz, MD, Don M. Benson, MD PhD, Nikoletta Lendvai, MD PhD, Frank Campana, MD, Eric Charpentier, Ravi Vij, MBBS, MD
Journal: Blood
Blood (2014) 124 (21): 83.
https://doi.org/10.1182/blood.V124.21.83.83
Published: 2014